Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1982 1
1993 1
1994 1
1997 1
2001 2
2004 1
2006 1
2007 2
2008 1
2009 1
2010 3
2011 5
2012 2
2013 5
2014 3
2015 4
2016 2
2017 3
2018 2
2019 2
2020 2
2021 6
2022 4
2023 4
2024 5
2025 13
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
Falchi L, Nijland M, Huang H, Linton KM, Seymour JF, Tao R, Kwiatek M, Costa A, Vassilakopoulos TP, Greil R, Jiménez-Ubieto A, Gangatharan SA, Benjamini O, Thieblemont C, Tucci A, Elinder-Camburn A, Illes A, Novak J, Pavlovsky MA, McDonald A, Yoon DH, Maruyama D, Sunkersett G, Mei JP, Mukherjee N, Zhu F, Alshreef A, Favaro E, Morschhauser F; EPCORE FL-1 Investigators. Falchi L, et al. Among authors: favaro e. Lancet. 2026 Jan 10;407(10524):161-173. doi: 10.1016/S0140-6736(25)02360-8. Epub 2025 Dec 7. Lancet. 2026. PMID: 41371238 Free article. Clinical Trial.
FINDINGS: Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, Australia, Europe, North America, and South America, a total of 488 participants were randomly allocated, 243 to epcoritamab plus R( …
FINDINGS: Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, …
Psychometric validation of the Italian Gender Preoccupation and Stability Questionnaire in a gender-diverse clinical sample.
Meneguzzo P, Dal Brun D, Scala A, Bonato M, Garolla A, Miscioscia M, Tenconi E, Favaro A; Gender Incongruence Interdisciplinary Group (GIIG). Meneguzzo P, et al. Among authors: favaro a. BJPsych Open. 2025 Oct 28;11(6):e258. doi: 10.1192/bjo.2025.10879. BJPsych Open. 2025. PMID: 41146457 Free PMC article.

The GPSQ showed solid internal consistency (alpha = 0.78; omega = 0.73) and excellent test-retest reliability (r = 0.98; intraclass correlation coefficient 0.98). Higher scores correlated with psychological distress (r = 0.55, p < 0.001) and body image concerns (

…
The GPSQ showed solid internal consistency (alpha = 0.78; omega = 0.73) and excellent test-retest reliability (r = 0.98; intraclass c …
Validity and Reliability of the CSAI-2R in DPT Students.
Favaro L, Guan Z, Middleton C, Schaeffer K, Zheng J, Bogulski J. Favaro L, et al. J Phys Ther Educ. 2025 Oct 7. doi: 10.1097/JTE.0000000000000436. Online ahead of print. J Phys Ther Educ. 2025. PMID: 41100902 Free article.

Acceptable internal consistency values were found for both surveys (1 = 0.79-0.91, 2 = 0.84-0.93), and statistically significant test-retest reliability was found, r = 0.53 (P < .01, 95% CI 0.24-0.73). Prior to the first practical examination, 36 first-year DPT students

…
Acceptable internal consistency values were found for both surveys (1 = 0.79-0.91, 2 = 0.84-0.93), and statistically significant test-retest …
Subcutaneous epcoritamab monotherapy in Japanese patients with relapsed or refractory follicular lymphoma: primary results of the EPCORE NHL-3 trial.
Izutsu K, Akahane D, Toubai T, Saito T, Mishima Y, Fujisaki T, Nishikori M, Kumode T, Suehiro Y, Ishitsuka K, Conlon R, Takahashi A, D'Angelo Månsson B, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: favaro e. Leuk Lymphoma. 2025 Oct;66(10):1913-1921. doi: 10.1080/10428194.2025.2525983. Epub 2025 Jul 9. Leuk Lymphoma. 2025. PMID: 40632620 Free article. Clinical Trial.
An unmet need exists for patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose disease remains incurable. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for R/R FL and different types of R/R larg …
An unmet need exists for patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose disease remains incurable. …
Validating the Gender Variance Scale in Italian: Psychometric Properties and Associations with Health and Sociodemographic Factors.
Meneguzzo P, Dal Brun D, Tenconi E, Bonato M, Scala A, Miscioscia M, Garolla A, Favaro A. Meneguzzo P, et al. Among authors: favaro a. Healthcare (Basel). 2025 Sep 25;13(19):2438. doi: 10.3390/healthcare13192438. Healthcare (Basel). 2025. PMID: 41095523 Free PMC article.
The GVS distinguished between gender identity groups: TGD participants scored higher than cisgender peers, and non-binary individuals reported significantly lower scores than both binary groups. Test-retest reliability was strong (r = 0.87-0.99; ICC = 0.992-0.996). Conclus …
The GVS distinguished between gender identity groups: TGD participants scored higher than cisgender peers, and non-binary individuals report …
Clinical representativeness of pivotal trials for T-cell engagers in relapsed/refractory follicular lymphoma.
Ding Z, Zhang G, Yu J, Wang T, Kamalakar R, Bains Chawla S, Chhibber A, Wang A, Alshreef A, Tybor D, Marques Goncalves F, Rivas Navarro F, Atiya M, Favaro E, Mutebi A. Ding Z, et al. Among authors: favaro e. Future Oncol. 2025 Sep;21(21):2795-2801. doi: 10.1080/14796694.2025.2543673. Epub 2025 Aug 13. Future Oncol. 2025. PMID: 40799045 Free PMC article.
AIM: To characterize trial populations of T-cell-engaging therapies, including bispecific antibodies and chimeric antigen receptor T-cell therapies, for relapsed/refractory (R/R) follicular lymphoma (FL) after 2 systemic therapies and the extent to which they repres …
AIM: To characterize trial populations of T-cell-engaging therapies, including bispecific antibodies and chimeric antigen receptor T-cell th …
Adaptive peptide dispersions enable drying-induced biomolecule encapsulation.
Dave DR, Kassem S, Coste M, Xu L, Tayarani-Najjaran M, Podbevšek D, Colon-De Leon P, Zhang S, Ortuno Macias L, Sementa D, Pérez-Ferreiro M, Ayati NS, Choudhury MA, Veerasammy K, Doganata S, Zhong T, Weng C, Morales J, Favaro DC, Marianski M, Ahn SY, Obermeyer AC, Wang T, Li TD, Chen X, Tu R, He Y, Ulijn RV. Dave DR, et al. Among authors: favaro dc. Nat Mater. 2025 Sep;24(9):1465-1475. doi: 10.1038/s41563-025-02300-z. Epub 2025 Aug 5. Nat Mater. 2025. PMID: 40764824 Free PMC article.
Eco-concerns and risk for eating disorders and orthorexia nervosa.
Devecchi A, Ponzo V, Favaro E, Goitre I, Stella B, Pagliuca G, Cuniberti F, Abbate-Daga G, Donini LM, Bo S. Devecchi A, et al. Among authors: favaro e. J Affect Disord. 2025 Aug 15;383:117-122. doi: 10.1016/j.jad.2025.04.113. Epub 2025 Apr 23. J Affect Disord. 2025. PMID: 40280437

In a multiple regression model, both ORTO-R and EAT-26 scores were directly associated with eco-guilt (beta = 0.45, 95%CI 0.35-0.55, p < 0.001 and beta = 0.14, 95%CI 0.08-0.20, p < 0.001, respectively), habitual ecological worry (beta = 0.24, 95%CI 0.16-0.32, p <

…
In a multiple regression model, both ORTO-R and EAT-26 scores were directly associated with eco-guilt (beta = 0.45, 95%CI 0.35-0.55, …
70 results